Clinical diagnosis or pathologic of hepatocellular carcinoma (HCC) or metastatic liver cancers
Conditions
Interventions
Trial group:Multimodal Thermal Therapy
Control group:Radiofrequency ablation or microwave ablation therapy
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age of 18-75 years. 2. Clinical diagnosis or pathologic of hepatocellular carcinoma (HCC) or metastatic liver cancers. 3. Intrahepatic lesions with a diameter of =3.0×10^9/L,ANC>=1.5×10^9/L,PLT>=50×10^9/L,HGB>=90 g/L; (2) Liver Function: AST =60 mL/min (4) Coagulation Function: INR 2×10³ IU/mL may be enrolled but must receive antiviral therapy.*)
Exclusion criteria
Exclusion criteria: 1. Diffuse hepatocellular carcinoma (HCC), or with tumor thrombus in the main portal vein to secondary branches or hepatic veins. 2. Severe liver atrophy or excessively large tumor volume requiring ablation of =1/3 of the liver volume. 3. Uncorrectable coagulation dysfunction or severe hematologic abnormalities with a high risk of bleeding. 4. Active bacterial infection or fungal infection. 5. Previous or coexisting malignancies. 6. History of solid organ transplant or hepatic encephalopathy. 7. Current enrollment in another clinical trial or prior exposure to experimental therapies 8. Pregnant or breastfeeding, or preparing to pregnant. 9. Not suitable to participate in clinical trials judged by investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of immune activating response;Progression Free Survival (PFS);Percentage of Participants With Adverse Events (AEs); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate(ORR);Local Control Rate(LCR); | — |
Countries
China
Contacts
Public ContactLichao Xu
Fudan University Shanghai Cancer Center
Outcome results
None listed